secwatch.observer — SEC 8-K summary
======================================

Issuer:     iTeos Therapeutics, Inc. (—)
CIK:        0001808865
Form:       8-K
Filed at:   2025-05-28T23:59:59+00:00
Accession:  0000950170-25-078084
Event type: other_material
Sentiment:  negative
Materiality: 1.00
Item codes: 2.05, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iTeos Therapeutics to wind down operations after terminating belrestotug program and GSK collaboration
--------------------------------------------------------------------------------

- Will wind down operations; expects severance charges of $21.8M-$24.7M and other program wind-down costs of $11.1M.
- Exploring potential asset sales including EOS-984, EOS-215, and preclinical obesity program targeting ENT1.
- Wind down substantially complete in Q3 2025; clinical development programs to wind down thereafter.
- Amended employment agreements for CEO, COO, CMO with enhanced severance if terminated during change in control (excluding dissolution).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808865/000095017025078084/0000950170-25-078084-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808865/000095017025078084/itos-20250527.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-078084

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer